WO2008131354A2 - Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment - Google Patents
Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment Download PDFInfo
- Publication number
- WO2008131354A2 WO2008131354A2 PCT/US2008/061055 US2008061055W WO2008131354A2 WO 2008131354 A2 WO2008131354 A2 WO 2008131354A2 US 2008061055 W US2008061055 W US 2008061055W WO 2008131354 A2 WO2008131354 A2 WO 2008131354A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- individual
- hedgehog signaling
- inhibiting
- genistein
- estrogenic agent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 46
- 239000003075 phytoestrogen Substances 0.000 title claims description 71
- 230000009459 hedgehog signaling Effects 0.000 title claims description 13
- 238000011282 treatment Methods 0.000 title description 7
- 239000000262 estrogen Substances 0.000 claims abstract description 52
- 230000008410 smoothened signaling pathway Effects 0.000 claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 108010038795 estrogen receptors Proteins 0.000 claims abstract description 17
- 102000015694 estrogen receptors Human genes 0.000 claims abstract description 8
- 235000006539 genistein Nutrition 0.000 claims description 61
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 61
- 229940045109 genistein Drugs 0.000 claims description 61
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 61
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 27
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 27
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 26
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 25
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 20
- UWBHHFACDVJLQC-UHFFFAOYSA-N spinacetin Natural products COc1c(O)cc2OC(=C(O)C(=O)c2c1O)c3ccc(O)c(C)c3 UWBHHFACDVJLQC-UHFFFAOYSA-N 0.000 claims description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 16
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 16
- 235000021283 resveratrol Nutrition 0.000 claims description 16
- 229940016667 resveratrol Drugs 0.000 claims description 16
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 14
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 14
- 229940015301 baicalein Drugs 0.000 claims description 14
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 13
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 13
- 235000012754 curcumin Nutrition 0.000 claims description 13
- 229940109262 curcumin Drugs 0.000 claims description 13
- 239000004148 curcumin Substances 0.000 claims description 13
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 13
- 235000005875 quercetin Nutrition 0.000 claims description 13
- 229960001285 quercetin Drugs 0.000 claims description 13
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 12
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 12
- 235000008714 apigenin Nutrition 0.000 claims description 12
- 229940117893 apigenin Drugs 0.000 claims description 12
- KDLBPPXQNXUTGJ-UHFFFAOYSA-N Patuletin Natural products C1=C(OC)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 KDLBPPXQNXUTGJ-UHFFFAOYSA-N 0.000 claims description 10
- XWIDINOKCRFVHQ-UHFFFAOYSA-N Spinacetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C(OC)=C(O)C=C3O2)O)=C1 XWIDINOKCRFVHQ-UHFFFAOYSA-N 0.000 claims description 10
- 235000007240 daidzein Nutrition 0.000 claims description 10
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 10
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000009498 luteolin Nutrition 0.000 claims description 10
- JMIFIYIEXODVTO-UHFFFAOYSA-N patuletin Chemical compound OC=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 JMIFIYIEXODVTO-UHFFFAOYSA-N 0.000 claims description 10
- PVNVIBOWBAPFOE-UHFFFAOYSA-N Dinoxanthin Natural products CC1(O)CC(OC(=O)C)CC(C)(C)C1=C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1(C(CC(O)C2)(C)C)C2(C)O1 PVNVIBOWBAPFOE-UHFFFAOYSA-N 0.000 claims description 9
- PGYAYSRVSAJXTE-CLONMANBSA-N all-trans-neoxanthin Chemical compound C(\[C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O PGYAYSRVSAJXTE-CLONMANBSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- OWAAYLVMANNJOG-OAKWGMHJSA-N neoxanthin Natural products CC(=C/C=C(C)/C=C/C=C(C)/C=C=C1C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC23OC2(C)CC(O)CC3(C)C OWAAYLVMANNJOG-OAKWGMHJSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 229940124606 potential therapeutic agent Drugs 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 3
- 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 7
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000004113 cell culture Methods 0.000 abstract description 4
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 206010060862 Prostate cancer Diseases 0.000 description 30
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 30
- 102100038595 Estrogen receptor Human genes 0.000 description 27
- 235000005911 diet Nutrition 0.000 description 23
- 210000002307 prostate Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 230000037213 diet Effects 0.000 description 19
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 18
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 17
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 17
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 15
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 12
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 11
- 229940011871 estrogen Drugs 0.000 description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 208000005623 Carcinogenesis Diseases 0.000 description 8
- 241000289669 Erinaceus europaeus Species 0.000 description 8
- 230000036952 cancer formation Effects 0.000 description 8
- 231100000504 carcinogenesis Toxicity 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000955 neuroendocrine Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 102000004874 Synaptophysin Human genes 0.000 description 5
- 108090001076 Synaptophysin Proteins 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 210000004412 neuroendocrine cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 4
- 235000008696 isoflavones Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 102000007345 Chromogranins Human genes 0.000 description 2
- 108010007718 Chromogranins Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 2
- 206010071019 Prostatic dysplasia Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100021796 Sonic hedgehog protein Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- -1 heterocyclic phenols Chemical class 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical class C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010057648 Cyclopia Diseases 0.000 description 1
- 241001219085 Cyclopia Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 241000489524 Veratrum californicum Species 0.000 description 1
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002272 genistein Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This disclosure pertains to prevention and suppression of tumor growth. More particularly, it relates to the use of phytoestrogens to delay and/or treat certain types of cancer.
- Cancer is one of the top health-related causes of human death.
- Prostate cancer is the most common form of non-skin cancer among men in the United States. See generally, Jemal et al. 2007 ' .
- the incidence of prostate cancer is believed to be controlled primarily by endocrine and dietary factors, as well as by genetic factors. Because prostate cancer typically develops later in life, identifying compounds that delay or inhibit the progression of this disease will have a significant impact on the incidence of this malignancy among the aging male population. Furthermore, because prostate cancer typically responds, at least initially, to endocrine and dietary mediators, new compounds that may inhibit tumor growth may be used in chemotherapy for treating patients who have already developed prostate cancer.
- soy products may contain such a compound that may serve as a superior alternative for cyclopamine. Dietary consumption of soy products has long been associated with reduced incidence of diseases such as cancer. A number of epidemiological studies have suggested that dietary intake of soy products may play a role in preventing prostate cancer. See Goetzl et al. 2007.
- the two primary isoflavone aglycones in soy are genistein and daidzein, which are heterocyclic phenols with structural homology to 17 ⁇ -estradiol. Because they possess estrogenic activity and are derived from plant sources, they are also known as phytoestrogens.
- Soy foods lacking isoflavones lose almost all cancer protection activity, suggesting that the isoflavones may be the key ingredient in soy that confers the anti-cancer activity (Barnes et al, 1994).
- Numerous models have been proposed to illuminate the underlying mechanisms through which soy isoflavones may affect the incidence of cancer or may interact with tumor cells .
- genistein has been found to be an inhibitor of tyrosine kinases, which play a critical role in tyrosine phosphorylation, signal transduction, mitogenic regulation, and cell cycle progression. Genistein has also been shown to inhibit angiogenesis.
- genistein acts as a potent antioxidant and inhibits topoisomerase II. Further, genistein induces apoptosis, which may limit tumor cell growth and metastasis.
- genistein may also act as an estrogen, interfering with and potentially altering growth and differentiation responses mediated through estrogen receptor (ER), including estrogen receptor alpha (ERa) and/or beta (ER ⁇ ). Soy genistein has been shown to bind both receptors with a higher affinity for ER ⁇ and initiate transcription of ER-dependent genes(Kuiper 1997). Dietary soy has been shown to inhibit the effects of neonatal estrogenization of the mouse prostate, perhaps by acting as a weak estrogen and blocking the effects of diethylstilbestrol (DES) through an ERa or ER ⁇ dependent-pathway.
- DES diethylstilbestrol
- phytoestrogens may be administered to an individual for preventing and/or treating cancer.
- the instrumentalities described herein advance the art by providing a new composition which may be used to prevent and/or treat cancer.
- the disclosure further provides a novel method for regulating the Hedgehog signaling pathway.
- Shh signaling pathway also called the “Hedgehog signaling pathway”
- the deregulation of the Shh signal-transduction pathway has been implicated in several cancers, including prostate cancer, basal cell carcinoma, medulloblastomas, glioma, sarcoma, colorectal cancer, tumors of the digestive tract, small cell lung cancer and pancreatic carcinoma (Sanchez et al., 2005).
- Hedgehog-signaling pathway components of the Hedgehog-signaling pathway, namely, SHH, PTCH, GLI, and in some cases, SMO, have been reported to be elevated in metastatic prostatic tumors versus normal prostates or non-metastatic tumors.
- Inhibitors of the Hedgehog pathway for example, cyclopamine or anti-SHH antibodies, have been shown to inhibit the growth of several well known human prostatic cell lines in vitro, including LNCaP and PC-3 (Sanchez et al., 2004). More importantly, in multiple xenograft models these same inhibitors worked extraordinarily well to inhibit tumor growth and metastases in vivo.
- the Hedgehog pathway culminates in the activation of transcription factors of the GIi family, namely, the GHl, GH2 and GH3 proteins (2002). Therefore, inhibition of GIi function might be a promising therapeutic target in certain tumors.
- the present disclosure shows for the first time that a number of phytoestrogens, including genistein, may inhibit the Hedgehog pathway, which may in turn lead to inhibition of tumor growth. It is shown that LNCaP and PC-3 cell proliferation may be regulated by a number of these phytoestrogens, such as genistein and EGCG.
- TRAMP-C2 cells which are derived from a mouse model for prostate cancer, TRAMP, may be used to study the effect of these phytoestrogens on cell proliferation and the underlying mechanisms.
- the proliferation of TRAMP-C2 cells may be inhibited when they are treated with certain phytoestrogens, including genistein and EGCG.
- certain phytoestrogens including genistein and EGCG.
- Most of the components of the Hedgehog signaling pathway are expressed in the TRAMP-C2 cells, suggesting that the pathway is likely to be activated in these cells.
- a number of phytoestrogens, including, for example, genistein and EGCG may down-regulate the expression of GHl, GH2 and GH3 in the TRAMP-C2 cells.
- compositions useful for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual may contain an estrogenic agent in an effective amount that is capable of inhibiting the Hedgehog signaling pathway in a cell.
- a method for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual.
- the method may comprise the step of administering to said individual an effective amount of an estrogenic agent, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in certain cells of said individual.
- This disclosure also provides another method for inhibiting Hedgehog signaling pathway in an individual with aberrant Hedgehog signaling.
- This method may include the steps of (a) determining whether Hedgehog signaling is abnormal in said individual, and (b) administering to said individual a Hedgehog signaling inhibiting effective amount of an estrogenic agent.
- this disclosure also provides a method for inhibiting Hedgehog signaling pathway in a cell, comprising contacting said cell with an estrogenic agent, said estrogenic agent being present in an amount that is effective in inhibiting expression of at least one GIi gene by at least 40%.
- Examples of estrogenic agents may include estrogens or their analogs, derivatives, esters, pharmaceutically acceptable salts, hydrates, or any combination thereof.
- the estrogen may be one that is produced by an animal, a plant, a fungal species, or a human being.
- the estrogen can be also produced by chemical synthesis or by biological engineering.
- the estrogen is a phytoestrogen.
- the composition may contain one or more members of phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
- the effective amount of an estrogenic agent is the amount of said estrogenic agent that can substantially reduce Hedgehog signaling in a cell. In another aspect, the effective amount of said estrogenic agent is the amount that is capable of binding to an estrogen receptor in said individual thereby inhibiting the Hedgehog signaling pathway in said individual. In another aspect, the effective amount of the estrogenic agent may be an amount of the estrogenic agent that is effective in reducing the expression of at least one GIi gene by at least 40%.
- the term "at least one GIi gene" means at least one member selected from the group consisting of GIi 1, Gli2 and Gli3.
- the agent may be an estrogenic agent, or any chemical compounds or proteins or polynucleotides that can bind an estrogen receptor to trigger downstream signaling events that include but are not limited to the Hedgehog signaling pathway.
- the present disclosure provides a screening method useful for identifying potential therapeutic agents that may be useful in treating or preventing cancer.
- the method may include the steps of: (a) contacting a cell with an intact Hedgehog signaling pathway with a candidate molecule; (b) monitoring changes in the activation of the Hedgehog signaling pathway; (c) determining whether said molecule is capable of inhibiting the Hedgehog signaling pathway, (d) identifying said molecule as a potential therapeutic agent if it is determined to be capable of inhibiting the Hedgehog signaling pathway.
- Compounds identified according to this screening method may be used for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual.
- FIG. 1 illustrate the chemical structures of some representative phytoestrogens along with the structures of 17 ⁇ -estradiol and cyclopamine.
- FIG. 2 shows expression of components of the Hedgehog-signaling pathway mRNA by RT-PCR in TRAMP-C2 cells.
- FIG. 3 shows expression of estrogen receptors mRNA by RT-PCR in the TRAMP-C2 cells.
- FIG. 4 shows the effects of seven phytoestrogens on the growth of TRAMP C2 cell line by measurement of total cellular protein.
- FIG. 5 shows inhibition of GIi 1 mRNA expression by the phytoestrogens by RT-PCR.
- FIG. 6 shows results of a dose response study on GIi 1 mRNA by real-time RT-PCR in which TRAMP C2 cells are treated with increasing amounts of genistein or EGCG.
- FIG. 7 A shows the result of a time course experiment in which the changes in GIi 1 levels in TRAMP-C2 cell line were followed for 72 hrs in the absence or presence of various phytoestrogens.
- Fig. 7B shows the effects of various phytoestrogens on Hedgehog signaling in a non-tumor cell line Shh Light II.
- Fig. 7C shows that Estradiol (E2) inhibits induction of GIi 1 transcription after 24 hours in TRAMP-C2 cells.
- FIG. 8 shows immunohistochemistry of TRAMP prostate tissues.
- FIG. 9 shows PDC "Neuroendocrine-like" Neoplasia Progression in Prostate Cancer.
- compositions and their therapeutic use may be applicable to other cancer types, including but not limited to breast cancer, colon cancer, and testicular cancer.
- the compositions may contain, in addition to the disclosed phytoestrogens, other components which are compatible with the phytoestrogen(s) to be given and may enhance the delivery, absorption, clinical effects or other aspects of the actions by such phytoestrogens. For instance, one may find it desirable to modify the phytoestrogens by conjugation or other methods to make them more stable.
- the compositions may be administered to a subject as medicinal pills, liquid injectibles or as dietary supplements.
- the methods of delivery may include, for example, oral delivery, blood injection, local injection or inhalation.
- this disclosure relates to the treatment and prevention of cancer. More particularly, the present disclosure provides 1) methods of preventing carcinogenesis in an individual; 2) methods of preventing the recurrence of, suppressing, inhibiting or reducing the incidence of carcinogenesis in an individual; 3) methods of treating an individual with cancer; 4) methods of suppressing, inhibiting or reducing the incidence of cancer in an individual; 5) methods of treating an individual with pre-malignant lesions of cancer; and 6) methods of suppressing, inhibiting or reducing the incidence of pre-malignant lesions of cancer in an individual, by administering to the individual a phytoestrogen, and/or an analog or metabolite thereof, derivative, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof.
- the present disclosure provides a safe and effective method for delaying or preventing the onset of prostate cancer, and is useful for treating an individual having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antigen (PSA), or having a family history of prostate cancer.
- This disclosure provides a method for administering to a subject an effective dose of a phytoestrogen to treat, prevent, suppress recurrence of, and/or inhibit prostate cancer and to treat, prevent, suppress recurrence of, and/or inhibit pre- malignant lesions of prostate cancer.
- the phytoestrogen is a compound belonging to the class of heterocyclic phenols, which are structurally similar to 17 ⁇ -estradiol.
- Suitable compounds may include, for examples, Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
- Genistein, Quercetin, Baicalein, Spinacetin, Patuletin, Luteolin and Apigenin may be categorized as isoflavones.
- Chemical structures of some representative phytoestrogens are shown in FIG. 1 along with the structures of 17 ⁇ -estradiol and cyclopamine.
- estrogenic agent refers to a chemical, a biologic, an organism, a mixture, an extract or combination thereof that may act as an estrogen or such an agent that may possess or may be induced to demonstrate a detectable estrogenic activity under certain conditions.
- estrogenic activity refers to a biological activity that is typically demonstrated by an estrogen when administered to an individual, regardless of whether the estrogen is produced by the individual or by other sources, such as plants or cell cultures.
- a phytoestrogen refers to an estrogenic agent that may be derived or prepared from any parts of a plant.
- the estrogenic agents of the present disclosure may be derived from natural resources such as plants, fungi or other organisms.
- the estrogenic agent is a phytoestrogen.
- the estrogenic agents of the present disclosure may be prepared through chemical synthesis or biological engineering.
- biological engineering may refer to activities including manipulation of a living cell in order to alter the behavior of the cell or to induce the cell to produce certain molecules in a quantity that is not typically produced by such a cell.
- the methods of the present disclosure comprise administration to a subject a pharmaceutically acceptable salt, ester, N- oxide, hydrate or mixtures thereof of the disclosed phytoestrogens and analogs thereof.
- the methods of the present disclosure comprise administration to a subject an analog and/or metabolite of the disclosed phytoestrogens and analogs thereof.
- a composition and/or a pharmaceutical composition may also be prepared containing the disclosed phytoestrogens and analogs thereof.
- the present disclosure provides a method of preventing carcinogenesis in a subject by oral administration to the subject a pharmaceutical composition containing from about 100 mg to about 600 mg of a phytoestrogen per kilogram (kg) by weight of the subject, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof.
- this disclosure provides a method of preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis, or increasing the survival rate of a subject having prostate cancer, said method including the step of oral administering to said subject a pharmaceutical composition containing from about 100 mg to about 600 mg of a phytoestrogen per kg by weight of the subject, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof.
- this disclosure provides a method of treating cancer, preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis, or increasing the survival rate of a subject having cancer, said method including the step of oral administering to said subject a dietary composition containing from about 10 mg to about 10 grams of a phytoestrogen, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof, per kg of diet to be consumed by said subject. It is to be understood that the amount of said phytoestrogen in the composition may be increased if a more drastic effect is desired up to a maximum dose that can be tolerated by the subject.
- the pharmaceutical composition containing a phytoestrogen may be administered by injection or other methods in such an amount so that the phytoestrogen may be delivered to a site within the subject's body and form a local concentration at the site that is sufficient to suppress the GIi 1 gene expression by at least 40%.
- the concentration of phytoestrogen in cells at such a body site may be in the range of about 20-100 ⁇ M in the case of genistein, and about 10-150 ⁇ M in the case of EGCG. These ranges may be considered an effective concentration of the respective phytoestrogen in a cell that may effectively inhibit the Hedgehog signaling pathway in such a cell.
- a cell proliferation inhibiting effective amount refers to the amount of an agent that, when applied to a cell culture or when administered to an individual, is capable of reducing the rate of cell growth by at least 30%.
- U.S. Patent application publication No. 20050090457 by Schoenmakers et al. teaches a method for treating mammals with genistein and/or genistein analogues.
- a report by Takimoto et al. (2003) describes the pharmacokinetic and pharmacodynamic of unconjugated soy isoflavones administered to individuals with cancer.
- the subject may have an elevated risk of prostate cancer.
- the subject may have benign prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antigen (PSA).
- a pre-administration screening may also be conducted wherein each individual is subject to a test to determine if the Hedgehog signaling is sufficiently abnormal to justify treatment with the phytoestrogens of the present disclosure. Such screening may be performed by, for example, testing the mRNA or protein levels of various proteins in the Hedgehog pathway.
- abnormal means the level of a molecule of interest deviates from that in a normal cell by at least 20%.
- GUI mRNA levels are shown to be more than 20% higher than normal cells from the same individual or from comparable individuals of the general population, such individual may be characterized as having abnormal Hedgehog signaling, at least with respect to the tissue or organ tested.
- the genes encoding the GIi family proteins may be collectively referred to as the GIi genes.
- the terms “individual” and “subject” are used interchangeably, and may refer to a mammal, such as human or other animals.
- TRAMP mice used for the animal studies are as described by Greenberg et al., 1995.
- TRAMP C2 cell lines derived from the TRAMP mice are as described by Foster et al., 1997.
- Various plant derived agents may be prepared directly from the respective plant sources.
- the compounds are obtained from commercial sources. Cyclopamine is obtained from LC laboratories (it can also be obtained from Toronto chemicals), while genistein and EGCG are both from Sigma Co.
- ER ⁇ KO/TRAMP knock-out mice
- ER ⁇ KO/TRAMP or ERWT/TRAMP mice are fed diets containing 0 or 300 mg genistein/kg of diet.
- a significant protective effect of genistein is observed in the ERWT/TRAMP mice but not in the ER ⁇ KO/TRAMP and ER ⁇ KO/TRAMP mice, suggesting that both ERa and ER ⁇ may be essential for the response to this class of phytoestrogens, including genistein.
- genistein and EGCG were both able to reduce Patchedl mRNA levels by 70%.
- Resveratrol also reduced Glil and Patchedl mRNAs by 60% and 50%, respectively.
- Approximate IC50 values for pathway repression were determined as 30 ⁇ M for genistein, 20 ⁇ M for EGCG, and 5 ⁇ M for resveratrol. These concentrations may be easily obtainable pharmacologically in humans.
- Another experiment showed that Glil protein concentration in LNCaP cells was also significantly reduced by all three compounds, genistein, EGCG, and resveratrol, as determined by Western blot analysis.
- Genistein, EGCG, and resveratrol may regulate prostate cancer via inhibition of the Hedgehog signaling pathway.
- FIG. 7A shows result of a time course in which the concentration of Glil mRNA in the TRAMP-C2 cells are measured by real-time RT-PCR at multiple time points for 72 hrs following the addition of genistein, EGCG, or cyclopamine into the culture medium.
- the effects of various phytoestrogens on Hedgehog signaling in a non-tumor cell line Shh Light II were also assessed (Fig. 7B).
- Shh Light II cells were obtained from the ATCC. These cells, containing the Glil responsive promoter driving a luciferase reporter, are a standard tool used to assay Hedgehog pathway activity. Meloni et al., 2006. Cells were allowed to reach confluency in 24-well plates and subsequently treated with the selected phytoestrogens at the amount indicated on the figure, along with the stimulatory sonic hedgehog protein (obtained from R&D Systems). The cells were then grown for 24 hours in phenol red-free DMEM supplemented with 0.5% charcoal stripped fetal bovine serum. Cells were then lysed, and the luciferase and renilla activities of the cell lysates were measured. As shown in Fig.
- TRAMP mice [0058] The influence of estrogen on prostate cancer has been previously described in the Background section.
- groups of -30 male mice, either ER ⁇ KO/TRAMP, ER ⁇ KO/TRAMP or ERWT/TRAMP were fed diets containing 0 or 300 mg genistein/kg (See Table 1). Mice were fed the diets from weaning and were euthanized at 5 months of age. Prostates were dissected and prepared for histopathology.
- the tumor stage was assessed using ratings of normal (N), hyperplasia (HYP), prostatic intraepithelial neoplasia (PIN), well differentiated carcinoma (WDC), moderately differentiated carcinoma (MDC) or poorly differentiated carcinoma (PDC) See Wechter et al., 2000; also see http://thegreenberglab.fhcrc.org. To summarize the data, non-cancer was defined as N, HYP or PIN and cancer was defined as WDC, MDC or PDC (Table 1) The prostate tumor incidence was compared between mice fed with genistein diet and those fed with casein.
- TRAMP mice with wild-type ER were fed diets supplemented with various combinations of Curcumin (from Dr. Acharan, and added to a final concentration of 10 gram/kg of the diet), Resveratrol (from Sigma, and added to a final concentration of 10 mg/kg of the diet), EGCG (from Sigma, and added to a final concentration of 100 mg/kg of the diet), Genistein (from LC laboratories, and added to a final concentration of 250 mg/kg of the diet), Quercetin (from Sigma, and added to a final concentration of 1 gram/kg of the diet), Baicalein (from Dr.
- FIG. 8 Shown in FIG. 8 are representative tissue samples from two ERWT/TRAMP mice fed genistein with HYP (FIG. 8A) from the dorsal lobe or PDC (FIG. 8B) from the ventral lobe. In both panels, the brown regions represent immunoreactivity.
- HYP prostate epithelium does not express chromogranin and synaptophysin (cytoplasmic neuroendocrine (NE) markers) or ERa (nuclear receptor). There is expression of ER ⁇ and androgen receptor in epithelial and stromal cells, as has been reported for normal prostate epithelium in man and mouse (Prins et al, 1998).
- the SV40 immunoreactivity confirms the expression of the transgene in the nucleus of the prostate epithelium.
- the immunoreactivity to this panel of antibodies of the HYP prostate was not different from those fed casein. As shown in FIG. 8B, these markers differed in PDC tissues. There was no difference between casein and genistein fed mice.
- NE carcinoma in this TRAMP model did express neuroendocrine markers, with 80% of sections expressing synaptophysin, and 30% expressing chromogranin. Androgen receptor reactivity diminished from occasional weak positives to uniformly negative. Transgene expression was maintained in NE cells.
- the pattern of estrogen receptor immunoreactivity switched, with nearly complete loss of ER ⁇ expression and gain of ERa expression.
- the pattern of ERa immunoreactivity was predominantly in clusters of NE cells scattered throughout the tumor mass and not in all NE cells.
- ERa expression was also observed in PIN and well-differentiated adenocarcinoma cells in both diet groups. Hence, distinct cancer origins appear to occur in the TRAMP prostate and these are independent of diet.
- FIG. 9A shows basal cells in the prostate ducts are positive for synaptophysin, a marker of neuroendocrine cells.
- FIG. 9B shows a focus of neuroendocrine cell proliferation, the earliest stage of neuroendocrine-like neoplasia.
- FIG. 9C shows the neoplastic neuroendocrine cells penetrate through the wall of the prostate tubule and proliferate in the stroma, encroaching adjacent tubules.
- FIG. 9D shows neoplastic neuroendocrine cells eventually surround the urethra.
- ERa and ER ⁇ may have opposing roles in the prostate in regard to prostate cancer and that ERa facilitates the development of PDC, while ER ⁇ plays a protective role in prostate cancer.
- This role is supported in the literature. See e.g., Imamov et al., 2004, and Signoretti et al, 2001. The balance between ERa and ER ⁇ seems to have a significant role in the development of PDC.
Abstract
A new method is provided for inhibiting tumor growth and for delaying the onset of cancer. Several estrogenic compounds from plants are capable of inhibiting cell proliferation both in cell cultures and in whole animals. These compounds likely exert their anti-proliferation effects by inhibiting the Hedgehog signaling pathway. Estrogen receptors may also play an essential role in the inhibitory effect of these compounds.
Description
PHYTOESTROGENS AS REGULATORS OF HEDGEHOG SIGNALING AND METHODS OF THEIR USE IN CANCER TREATMENT
RELATED APPLICATION [0001] This application claims priority to U.S. provisional application
Serial No. 60/925,661 filed April 20, 2007, which is hereby incorporated by reference.
BACKGROUND
1. Field of the Invention [0002] This disclosure pertains to prevention and suppression of tumor growth. More particularly, it relates to the use of phytoestrogens to delay and/or treat certain types of cancer.
2. Description of Related Art [0003] Cancer is one of the top health-related causes of human death.
Prostate cancer is the most common form of non-skin cancer among men in the United States. See generally, Jemal et al. 2007 '. The incidence of prostate cancer is believed to be controlled primarily by endocrine and dietary factors, as well as by genetic factors. Because prostate cancer typically develops later in life, identifying compounds that delay or inhibit the progression of this disease will have a significant impact on the incidence of this malignancy among the aging male population. Furthermore, because prostate cancer typically responds, at least initially, to endocrine and dietary mediators, new compounds that may inhibit tumor growth may be used in chemotherapy for treating patients who have already developed prostate cancer.
[0004] Despite extensive search for plant derived compounds ("botanical compounds") that may delay and/or suppress cancerous growth, only a small number of plant derived candidate cancer cures/treatments have been identified. One of these is cyclopamine, which was originally isolated from Veratrum californicum in the 1960s (Keeler et al., 1970). Cyclopamine has recently been shown to result in complete regression of xenograft tumors in mice (Karhadkar et al., 2004).
[0005] Although cyclopamine exists naturally, it has been known to cause birth defects, most notably cyclopia, namely, the fusion of two eyes into one central
eye in the progeny (Keeler et al., 1970). Thus, the use of cyclopamine in the laboratory or in a clinical setting may pose a hazard to health care professionals, patients and researches. In addition, cyclopamine is very expensive and may not be as effective as has initially been suggested. Recent reports suggest that the effects of cyclopamine may be limited only to PDC (poorly differentiated carcinoma) type or highly aggressive tumors in mice. See - Sanchez et al. 2005, Karhadkar et al. 2004. There is therefore a need for a safer, less expensive and more effective compound for treating and/or preventing prostate cancer.
[0006] Several lines of evidence suggest that soy products may contain such a compound that may serve as a superior alternative for cyclopamine. Dietary consumption of soy products has long been associated with reduced incidence of diseases such as cancer. A number of epidemiological studies have suggested that dietary intake of soy products may play a role in preventing prostate cancer. See Goetzl et al. 2007. The two primary isoflavone aglycones in soy are genistein and daidzein, which are heterocyclic phenols with structural homology to 17β-estradiol. Because they possess estrogenic activity and are derived from plant sources, they are also known as phytoestrogens. Soy foods lacking isoflavones lose almost all cancer protection activity, suggesting that the isoflavones may be the key ingredient in soy that confers the anti-cancer activity (Barnes et al, 1994). [0007] Numerous models have been proposed to illuminate the underlying mechanisms through which soy isoflavones may affect the incidence of cancer or may interact with tumor cells . For instance, genistein has been found to be an inhibitor of tyrosine kinases, which play a critical role in tyrosine phosphorylation, signal transduction, mitogenic regulation, and cell cycle progression. Genistein has also been shown to inhibit angiogenesis. In addition to its inhibition of mitochondrial aldehyde dehydrogenase, which may limit tumor cell growth, genistein acts as a potent antioxidant and inhibits topoisomerase II. Further, genistein induces apoptosis, which may limit tumor cell growth and metastasis.
[0008] Last but not least, genistein may also act as an estrogen, interfering with and potentially altering growth and differentiation responses mediated through estrogen receptor (ER), including estrogen receptor alpha (ERa) and/or beta (ERβ). Soy genistein has been shown to bind both receptors with a higher affinity for ERβ and initiate transcription of ER-dependent genes(Kuiper 1997). Dietary soy has been shown to inhibit the effects of neonatal estrogenization of the mouse prostate, perhaps
by acting as a weak estrogen and blocking the effects of diethylstilbestrol (DES) through an ERa or ERβ dependent-pathway. In the rat dorsolateral prostate, genistein was shown to inhibit the expression of epidermal growth factor (EGF) and ErbB2/Neu receptors. [0009] Studies in cultured cells have demonstrated that soy phytoestrogens, such as genistein, inhibit the growth of prostate cancer cell lines in vitro. See Shenouda et al. 2004. Previous work by Mentor-Marcel et al (2001) identified a protective effect of genistein in reducing poorly differentiated carcinoma (PDF) in the TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mouse model. [0010] Together these studies suggest that phytoestrogens such as genistein may play an important role in the prevention or inhibition of cancer development. However, no studies have directly characterized the responses of normal and cancer cells to these phytoestrogens in vivo. More importantly, no studies have directly linked phytoestrogens and their anti-cancer activity to an underlying cellular pathway that is implicated in cell proliferation or cell differentiation
(Karhadkar et al, 2004). There is therefore a need for an established method whereby phytoestrogens may be administered to an individual for preventing and/or treating cancer.
SUMMARY
[0011] The instrumentalities described herein advance the art by providing a new composition which may be used to prevent and/or treat cancer. The disclosure further provides a novel method for regulating the Hedgehog signaling pathway.
[0012] Recent studies have implicated Hedgehog signaling pathway in a variety of malignancies. The Sonic Hedgehog (Shh) signal transduction pathway
(also called the "Hedgehog signaling pathway") is crucial to the growth, survival and organization of many cells, tissues and organs. For review, see Datta (2006). The deregulation of the Shh signal-transduction pathway has been implicated in several cancers, including prostate cancer, basal cell carcinoma, medulloblastomas, glioma, sarcoma, colorectal cancer, tumors of the digestive tract, small cell lung cancer and pancreatic carcinoma (Sanchez et al., 2005).
[0013] Briefly, components of the Hedgehog-signaling pathway, namely, SHH, PTCH, GLI, and in some cases, SMO, have been reported to be elevated in metastatic prostatic tumors versus normal prostates or non-metastatic tumors.
Inhibitors of the Hedgehog pathway, for example, cyclopamine or anti-SHH antibodies, have been shown to inhibit the growth of several well known human prostatic cell lines in vitro, including LNCaP and PC-3 (Sanchez et al., 2004). More importantly, in multiple xenograft models these same inhibitors worked extraordinarily well to inhibit tumor growth and metastases in vivo. According to Ruiz I Altaba et al., the Hedgehog pathway culminates in the activation of transcription factors of the GIi family, namely, the GHl, GH2 and GH3 proteins (2002). Therefore, inhibition of GIi function might be a promising therapeutic target in certain tumors. [0014] Little work has been done to explore any potential cross-talk between phytoestrogens and the Hedgehog signaling pathway. The present disclosure shows for the first time that a number of phytoestrogens, including genistein, may inhibit the Hedgehog pathway, which may in turn lead to inhibition of tumor growth. It is shown that LNCaP and PC-3 cell proliferation may be regulated by a number of these phytoestrogens, such as genistein and EGCG. TRAMP-C2 cells, which are derived from a mouse model for prostate cancer, TRAMP, may be used to study the effect of these phytoestrogens on cell proliferation and the underlying mechanisms. The proliferation of TRAMP-C2 cells may be inhibited when they are treated with certain phytoestrogens, including genistein and EGCG. [0015] Most of the components of the Hedgehog signaling pathway are expressed in the TRAMP-C2 cells, suggesting that the pathway is likely to be activated in these cells. A number of phytoestrogens, including, for example, genistein and EGCG may down-regulate the expression of GHl, GH2 and GH3 in the TRAMP-C2 cells. [0016] It has previously been shown that soy genistein, ERa (estrogen receptor a) and ERβ have dramatically different effects on tumorigenesis in the TRAMP mouse model. Additionally, a recent paper suggests that ERβ, but not ERa, works through the dihydrotestosterone metabolite, 5α-androstane-3β,17β-diol, to regulate E-cadherin in prostate cancer (Guerini, 2005). Soy phytoestrogen preferentially binds to ERβ over ERa.
[0017] It is hereby disclosed a composition useful for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual. The
composition may contain an estrogenic agent in an effective amount that is capable of inhibiting the Hedgehog signaling pathway in a cell.
[0018] In another embodiment, a method is provided for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual. The method may comprise the step of administering to said individual an effective amount of an estrogenic agent, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in certain cells of said individual.
[0019] This disclosure also provides another method for inhibiting Hedgehog signaling pathway in an individual with aberrant Hedgehog signaling. This method may include the steps of (a) determining whether Hedgehog signaling is abnormal in said individual, and (b) administering to said individual a Hedgehog signaling inhibiting effective amount of an estrogenic agent. Alternatively, this disclosure also provides a method for inhibiting Hedgehog signaling pathway in a cell, comprising contacting said cell with an estrogenic agent, said estrogenic agent being present in an amount that is effective in inhibiting expression of at least one GIi gene by at least 40%.
[0020] Examples of estrogenic agents may include estrogens or their analogs, derivatives, esters, pharmaceutically acceptable salts, hydrates, or any combination thereof. For purpose of this disclosure, the estrogen may be one that is produced by an animal, a plant, a fungal species, or a human being. The estrogen can be also produced by chemical synthesis or by biological engineering. In a preferred embodiment, the estrogen is a phytoestrogen. In one aspect, the composition may contain one or more members of phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
[0021] In one aspect, the effective amount of an estrogenic agent is the amount of said estrogenic agent that can substantially reduce Hedgehog signaling in a cell. In another aspect, the effective amount of said estrogenic agent is the amount that is capable of binding to an estrogen receptor in said individual thereby inhibiting the Hedgehog signaling pathway in said individual. In another aspect, the effective amount of the estrogenic agent may be an amount of the estrogenic agent that is effective in reducing the expression of at least one GIi gene by at least 40%. For
purpose of this disclosure, the term "at least one GIi gene" means at least one member selected from the group consisting of GIi 1, Gli2 and Gli3.
[0022] It is also disclosed a method for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual, comprising administering to said individual an effective amount of an agent, wherein said agent in said effective amount is capable of binding at least one estrogen receptor in the individual, thereby inhibiting the Hedgehog signaling pathway in said individual. For purpose of this disclosure, the agent may be an estrogenic agent, or any chemical compounds or proteins or polynucleotides that can bind an estrogen receptor to trigger downstream signaling events that include but are not limited to the Hedgehog signaling pathway.
[0023] In yet another embodiment, the present disclosure provides a screening method useful for identifying potential therapeutic agents that may be useful in treating or preventing cancer. The method may include the steps of: (a) contacting a cell with an intact Hedgehog signaling pathway with a candidate molecule; (b) monitoring changes in the activation of the Hedgehog signaling pathway; (c) determining whether said molecule is capable of inhibiting the Hedgehog signaling pathway, (d) identifying said molecule as a potential therapeutic agent if it is determined to be capable of inhibiting the Hedgehog signaling pathway. Compounds identified according to this screening method may be used for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual.
BRIEF DESCRIPTION OF THE FIGURES
[0024] FIG. 1 illustrate the chemical structures of some representative phytoestrogens along with the structures of 17β-estradiol and cyclopamine.
[0025] FIG. 2 shows expression of components of the Hedgehog-signaling pathway mRNA by RT-PCR in TRAMP-C2 cells.
[0026] FIG. 3 shows expression of estrogen receptors mRNA by RT-PCR in the TRAMP-C2 cells.
[0027] FIG. 4 shows the effects of seven phytoestrogens on the growth of TRAMP C2 cell line by measurement of total cellular protein. [0028] FIG. 5 shows inhibition of GIi 1 mRNA expression by the phytoestrogens by RT-PCR.
[0029] FIG. 6 shows results of a dose response study on GIi 1 mRNA by real-time RT-PCR in which TRAMP C2 cells are treated with increasing amounts of genistein or EGCG.
[0030] FIG. 7 A shows the result of a time course experiment in which the changes in GIi 1 levels in TRAMP-C2 cell line were followed for 72 hrs in the absence or presence of various phytoestrogens. Fig. 7B shows the effects of various phytoestrogens on Hedgehog signaling in a non-tumor cell line Shh Light II. Fig. 7C shows that Estradiol (E2) inhibits induction of GIi 1 transcription after 24 hours in TRAMP-C2 cells.
[0031] FIG. 8 shows immunohistochemistry of TRAMP prostate tissues. [0032] FIG. 9 shows PDC "Neuroendocrine-like" Neoplasia Progression in Prostate Cancer.
DETAILED DESCRIPTION
[0033] It is to be understood that this disclosure teaches by way of example, and not by limitation. The instrumentalities described herein are broader than the particular methods and materials, which may vary within the skill of the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. Names of chemicals, proteins, genes and pathways may be referred to using either small or capital letters, which shall be interpreted to refer to the same. As used throughout this disclosure, references by author name and publication year are more particularly cited in the References section. Further, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the related art. The following terminology and grammatical variants are used in accordance with the definitions set out below.
[0034] The materials and methods described herein relate to the use of phytoestrogens to prevent or to treat certain cancers. Although prostate cancer is used as a model for the present disclosure, the compositions and their therapeutic use may be applicable to other cancer types, including but not limited to breast cancer, colon cancer, and testicular cancer. The compositions may contain, in addition to the disclosed phytoestrogens, other components which are compatible with the phytoestrogen(s) to be given and may enhance the delivery, absorption, clinical effects or other aspects of the actions by such phytoestrogens. For instance, one may find it desirable to modify the phytoestrogens by conjugation or other methods to make them more stable. The compositions may be administered to a subject as
medicinal pills, liquid injectibles or as dietary supplements. The methods of delivery may include, for example, oral delivery, blood injection, local injection or inhalation.
[0035] In another aspect, this disclosure relates to the treatment and prevention of cancer. More particularly, the present disclosure provides 1) methods of preventing carcinogenesis in an individual; 2) methods of preventing the recurrence of, suppressing, inhibiting or reducing the incidence of carcinogenesis in an individual; 3) methods of treating an individual with cancer; 4) methods of suppressing, inhibiting or reducing the incidence of cancer in an individual; 5) methods of treating an individual with pre-malignant lesions of cancer; and 6) methods of suppressing, inhibiting or reducing the incidence of pre-malignant lesions of cancer in an individual, by administering to the individual a phytoestrogen, and/or an analog or metabolite thereof, derivative, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof.
[0036] In one embodiment, the present disclosure provides a safe and effective method for delaying or preventing the onset of prostate cancer, and is useful for treating an individual having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antigen (PSA), or having a family history of prostate cancer. [0037] This disclosure provides a method for administering to a subject an effective dose of a phytoestrogen to treat, prevent, suppress recurrence of, and/or inhibit prostate cancer and to treat, prevent, suppress recurrence of, and/or inhibit pre- malignant lesions of prostate cancer. In one embodiment, the phytoestrogen is a compound belonging to the class of heterocyclic phenols, which are structurally similar to 17β-estradiol. Suitable compounds may include, for examples, Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof. Of these, Genistein, Quercetin, Baicalein, Spinacetin, Patuletin, Luteolin and Apigenin may be categorized as isoflavones. Chemical structures of some representative phytoestrogens are shown in FIG. 1 along with the structures of 17β-estradiol and cyclopamine.
[0038] The term "estrogenic agent" refers to a chemical, a biologic, an organism, a mixture, an extract or combination thereof that may act as an estrogen or such an agent that may possess or may be induced to demonstrate a detectable estrogenic activity under certain conditions. The term "estrogenic activity" refers to a
biological activity that is typically demonstrated by an estrogen when administered to an individual, regardless of whether the estrogen is produced by the individual or by other sources, such as plants or cell cultures. A phytoestrogen refers to an estrogenic agent that may be derived or prepared from any parts of a plant. [0039] It is to be understood that the estrogenic agents of the present disclosure may be derived from natural resources such as plants, fungi or other organisms. In a preferred embodiment, the estrogenic agent is a phytoestrogen. Alternatively, the estrogenic agents of the present disclosure may be prepared through chemical synthesis or biological engineering. For purpose of this disclosure, biological engineering may refer to activities including manipulation of a living cell in order to alter the behavior of the cell or to induce the cell to produce certain molecules in a quantity that is not typically produced by such a cell.
[0040] In another embodiment, the methods of the present disclosure comprise administration to a subject a pharmaceutically acceptable salt, ester, N- oxide, hydrate or mixtures thereof of the disclosed phytoestrogens and analogs thereof. In another embodiment, the methods of the present disclosure comprise administration to a subject an analog and/or metabolite of the disclosed phytoestrogens and analogs thereof. A composition and/or a pharmaceutical composition may also be prepared containing the disclosed phytoestrogens and analogs thereof.
[0041] Thus, the present disclosure provides a method of preventing carcinogenesis in a subject by oral administration to the subject a pharmaceutical composition containing from about 100 mg to about 600 mg of a phytoestrogen per kilogram (kg) by weight of the subject, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof.
[0042] In another embodiment, this disclosure provides a method of preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis, or increasing the survival rate of a subject having prostate cancer, said method including the step of oral administering to said subject a pharmaceutical composition containing from about 100 mg to about 600 mg of a phytoestrogen per kg by weight of the subject, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof.
[0043] In another embodiment, this disclosure provides a method of treating cancer, preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis, or increasing the survival rate of a subject having cancer, said method including the step of oral administering to said subject a dietary composition containing from about 10 mg to about 10 grams of a phytoestrogen, its ester or other derivatives, pharmaceutically acceptable salt, hydrate, or any combination thereof and/or an analog or metabolite thereof, per kg of diet to be consumed by said subject. It is to be understood that the amount of said phytoestrogen in the composition may be increased if a more drastic effect is desired up to a maximum dose that can be tolerated by the subject.
[0044] In yet another embodiment, the pharmaceutical composition containing a phytoestrogen may be administered by injection or other methods in such an amount so that the phytoestrogen may be delivered to a site within the subject's body and form a local concentration at the site that is sufficient to suppress the GIi 1 gene expression by at least 40%. By way of example, the concentration of phytoestrogen in cells at such a body site may be in the range of about 20-100 μM in the case of genistein, and about 10-150 μM in the case of EGCG. These ranges may be considered an effective concentration of the respective phytoestrogen in a cell that may effectively inhibit the Hedgehog signaling pathway in such a cell. For purpose of the present disclosure, a cell proliferation inhibiting effective amount refers to the amount of an agent that, when applied to a cell culture or when administered to an individual, is capable of reducing the rate of cell growth by at least 30%.
[0045] U.S. Patent application publication No. 20050090457 by Schoenmakers et al. teaches a method for treating mammals with genistein and/or genistein analogues. A report by Takimoto et al. (2003) describes the pharmacokinetic and pharmacodynamic of unconjugated soy isoflavones administered to individuals with cancer. These references are hereby expressly incorporated by reference.
[0046] In one aspect of this disclosure, the subject may have an elevated risk of prostate cancer. In another aspect, the subject may have benign prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antigen (PSA). A pre-administration screening may also be conducted wherein each individual is subject to a test to determine if the Hedgehog
signaling is sufficiently abnormal to justify treatment with the phytoestrogens of the present disclosure. Such screening may be performed by, for example, testing the mRNA or protein levels of various proteins in the Hedgehog pathway. The term "abnormal" means the level of a molecule of interest deviates from that in a normal cell by at least 20%. For example, if the GUI mRNA levels are shown to be more than 20% higher than normal cells from the same individual or from comparable individuals of the general population, such individual may be characterized as having abnormal Hedgehog signaling, at least with respect to the tissue or organ tested. The genes encoding the GIi family proteins may be collectively referred to as the GIi genes.
[0047] For purpose of this disclosure, the terms "individual" and "subject" are used interchangeably, and may refer to a mammal, such as human or other animals.
[0048J The TRAMP mice used for the animal studies are as described by Greenberg et al., 1995. The TRAMP C2 cell lines derived from the TRAMP mice are as described by Foster et al., 1997. Various plant derived agents may be prepared directly from the respective plant sources. To maintain a consistent standard with respect to the compounds used, for purpose of this disclosure, the compounds are obtained from commercial sources. Cyclopamine is obtained from LC laboratories (it can also be obtained from Toronto chemicals), while genistein and EGCG are both from Sigma Co.
[0049] In one aspect of the present disclosure, in order to determine the effect of genistein on prostate tumor development in the TRAMP mice and the underlying mechanisms, if any, ERαKO/TRAMP (KO=knock-out), ERβKO/TRAMP or ERWT/TRAMP mice are fed diets containing 0 or 300 mg genistein/kg of diet. A significant protective effect of genistein is observed in the ERWT/TRAMP mice but not in the ERαKO/TRAMP and ERβKO/TRAMP mice, suggesting that both ERa and ERβ may be essential for the response to this class of phytoestrogens, including genistein.
EXAMPLES
[0050] The following nonlimiting examples disclose general procedures, reagents and characterization methods that teach by way of example, and should not
be construed in a narrowing manner that limits the disclosure to what is specifically disclosed. Those skilled in the art will understand that numerous modifications may be made and still the result will fall within the spirit and scope of the present invention.
Example 1 TRAMP-C2 cell line expression of estrogen receptors and
Hedgehog path components
[0051] The expression profile of selected components of the Hedgehog- signaling pathway in the TRAMP-C2 cells was characterized. SHH, GIi 1, GIi 2 and GIi 3 were found to be expressed in these cells as determined by RT-PCR (FIG. 2). The expression of estrogen receptors in the TRAMP-C2 cells was analyzed using RT- PCR and western blots. Both receptors were found to be present in this cell line (FIG. 3). 100 bp ladder was loaded in lanes 1 and 4 of gels A & B, respectively. ERa primers span exons 5-8, ERβ primers span exons 8-9.
Example 2 Effects of phytoestrogens on Shh signaling in TRAMP-C2 and Shh
Light II cells
[0052] It has been shown that phytoestrogens in common herbs regulate prostate cancer cell growth in vitro (Shenouda et al., 2004). In order to determine whether these phytoestrogens also regulate cells derived from the mouse model of prostate cancer, the TRAMP-C2 cell line was treated with the soy phytoestrogen genistein and growth inhibition IC50 doses were determined (FIG. 4). Effects of the phytoestrogens genistein and EGCG on expression of these Hedgehog-pathway components were also determined by quantitative RT-PCR. Cyclopamine was used as a control. As shown in FIG. 5, genistein down-regulates Glil expression compared to the untreated control. GAPDH was used as an internal control.
[0053] Another experiment was carried out to determine the dosage response of these phytoestrogen on Glil expression in the TRAMP-C2 cell line. Increasing amounts of genistein or EGCG were added to cell cultures of TRAMP-C2, and the levels of Glil mRNA was determined by real time RT-PCR. The results of this experiment verifies a correlation between phytoestrogen treatment and Hedgehog activity (FIG. 6). A decrease in Glil mRNA levels by more than 80% was observed at the highest treatment concentrations of genistein or EGCG. This observation
suggests that phytoestrogens are likely to be major regulators, rather than merely effectors of the Hedgehog signaling pathway.
[0054] The RT-PCR results also showed that genistein and EGCG were both able to reduce Patchedl mRNA levels by 70%. Resveratrol also reduced Glil and Patchedl mRNAs by 60% and 50%, respectively. Approximate IC50 values for pathway repression were determined as 30μM for genistein, 20μM for EGCG, and 5μM for resveratrol. These concentrations may be easily obtainable pharmacologically in humans. Another experiment showed that Glil protein concentration in LNCaP cells was also significantly reduced by all three compounds, genistein, EGCG, and resveratrol, as determined by Western blot analysis. Thus, Genistein, EGCG, and resveratrol may regulate prostate cancer via inhibition of the Hedgehog signaling pathway.
[0055] FIG. 7A shows result of a time course in which the concentration of Glil mRNA in the TRAMP-C2 cells are measured by real-time RT-PCR at multiple time points for 72 hrs following the addition of genistein, EGCG, or cyclopamine into the culture medium. The suppression of Glil mRNA concentration by genistein and EGCG as used at a final concentration of 50 μM and 100 μM, respectively, was more pronounced than the effect of cyclopamine at a final concentration of 30 μM. [0056] The effects of various phytoestrogens on Hedgehog signaling in a non-tumor cell line Shh Light II were also assessed (Fig. 7B). Shh Light II cells were obtained from the ATCC. These cells, containing the Glil responsive promoter driving a luciferase reporter, are a standard tool used to assay Hedgehog pathway activity. Meloni et al., 2006. Cells were allowed to reach confluency in 24-well plates and subsequently treated with the selected phytoestrogens at the amount indicated on the figure, along with the stimulatory sonic hedgehog protein (obtained from R&D Systems). The cells were then grown for 24 hours in phenol red-free DMEM supplemented with 0.5% charcoal stripped fetal bovine serum. Cells were then lysed, and the luciferase and renilla activities of the cell lysates were measured. As shown in Fig. 7B, similar to the effects exerted by cyclopamine, both genistein and curcumin also inhibit hedgehog activity as evidenced by the decrease in luciferase reporter activity.
[0057] In order to test whether the inhibitory effect of genistein on GUI transcription is through ERa or ERβ, experiments were conducted to determine whether 17β-estradiol (E2) works in the same manner as genistein (Fig. 7C). Strong inhibition of GIi 1 expression was observed with 1OnM E2. Addition of genistein did not enhance this inhibition by E2, suggesting that both compounds may act through the Estrogen Receptors.
Example 3 Anti-tumor Effects of phytoestrogens as dietary supplements in
TRAMP mice [0058] The influence of estrogen on prostate cancer has been previously described in the Background section. In order to determine the effect of genistein on prostate tumor development in the TRAMP model, in the first experiment, groups of -30 male mice, either ERαKO/TRAMP, ERβKO/TRAMP or ERWT/TRAMP were fed diets containing 0 or 300 mg genistein/kg (See Table 1). Mice were fed the diets from weaning and were euthanized at 5 months of age. Prostates were dissected and prepared for histopathology. The tumor stage was assessed using ratings of normal (N), hyperplasia (HYP), prostatic intraepithelial neoplasia (PIN), well differentiated carcinoma (WDC), moderately differentiated carcinoma (MDC) or poorly differentiated carcinoma (PDC) See Wechter et al., 2000; also see http://thegreenberglab.fhcrc.org. To summarize the data, non-cancer was defined as N, HYP or PIN and cancer was defined as WDC, MDC or PDC (Table 1) The prostate tumor incidence was compared between mice fed with genistein diet and those fed with casein. A significant protective effect of genistein was observed in the ERWT/TRAMP mice but not in the ERαKO/TRAMP and ERβKO/TRAMP mice, suggesting that both ERa and ERβ are essential for the response to genistein (See Table 2).
Table 1 Incidence of prostate tumorigenesis in ERαKO/TRAMP,
ERβKO/TRAMP and ERWT/TRAMP mice fed with 300 mg genistein/kg diet
Phenotype
Genotype All Diet n Non-Cancer Cancer
TRAMP Normal HYP PIN WDC MDC PDC
(Stagel) (2) (3) (4) (5) (6)
ERWT Casern 74 1(1 4%) 12(16 2%) 11(14 9%) 35(47 2%) 0 15(20 3%)
ERWT Gemstem 54 0 15(28%) 18(33%) 7(13%) 1(2%) 13(24%)
ERaKO Casem 79 0 2(3 0%) 4(5%) 68(86%) 1(1%) 4(5%)
ERaKO Gemstem 26 1(3 8%) 0 1(3 8%) 23(88 6%) 1(3 8%) 0
ERβKO Casem 21 0 0 5(24%) 6(28%) 0 10(48%)
ERβKO Gemstem 21 0 0 4(19%) 7(33%) 0 10(48%)
Table 2 Statistical Comparisons
1. CANCER (4-6) versus NON CANCER (1-3) a- ER-WT casein versus ER-WT Gemstem P= 0 0013 Significant b- ERaKO casem versus ERaKO gemstem P= 0 68 Non significant c- ERβKO casem versus ERβKO gemstem P= 0 71 Non Significant
2. PDC versus NON-PDC a- ER-WT casem versus ERaKO casem P= 0 0002 Significant b- ER-WT casem versus ERβKO casem P= 0 019 Significant c- ER-WT gemstem versus ERaKO gemstem P= <0 0001 Significant d- ER-WT gemstem versus ERβKO gemstem P= 0 047 Significant
[0059] In order to assess the effects of other phytoestrogens on prostate cancer, TRAMP mice with wild-type ER were fed diets supplemented with various combinations of Curcumin (from Dr. Acharan, and added to a final concentration of 10 gram/kg of the diet), Resveratrol (from Sigma, and added to a final concentration of 10 mg/kg of the diet), EGCG (from Sigma, and added to a final concentration of 100 mg/kg of the diet), Genistein (from LC laboratories, and added to a final concentration of 250 mg/kg of the diet), Quercetin (from Sigma, and added to a final concentration of 1 gram/kg of the diet), Baicalein (from Dr. Acharan, and added to a final concentration of 150 mg/kg of the diet), and Apigenm (from LC laboratories, and added to a final concentration of 15 mg/kg of the diet). Curcumm is also commercially available from NOW Foods (Bloomingdale IL), and Baicalein is also commercially available from Caymen Chemicals (Ann Arbor, Michigan). The results of this study indicate that both Mix 3 and Mix 4 significantly delay and/or prevent the occurrence of prostate cancer in these mice (Table 3).
Table 3 Incidence of prostate tumorigenesis in ERWT/TRAMP mice fed with diet supplemented with combination of phytoestrogens
Mix 3 = Curcumin + Resveratrol + EGCG Mix 4 = Genistein + Quercetin + Baicalein ■ Apigenin Pure 7 = Mix 3 + Mix 4
Example 4 Immunohistochemical Analyses of the TRAMP Mouse
[0060] Immunohistochemical analyses of neuroendocrine marker and hormone receptor expression in the prostates from TRAMP mice were conducted.
Shown in FIG. 8 are representative tissue samples from two ERWT/TRAMP mice fed genistein with HYP (FIG. 8A) from the dorsal lobe or PDC (FIG. 8B) from the ventral lobe. In both panels, the brown regions represent immunoreactivity. HYP prostate epithelium does not express chromogranin and synaptophysin (cytoplasmic neuroendocrine (NE) markers) or ERa (nuclear receptor). There is expression of ERβ and androgen receptor in epithelial and stromal cells, as has been reported for normal prostate epithelium in man and mouse (Prins et al, 1998). The SV40 immunoreactivity confirms the expression of the transgene in the nucleus of the prostate epithelium. The immunoreactivity to this panel of antibodies of the HYP prostate was not different from those fed casein. As shown in FIG. 8B, these markers differed in PDC tissues. There was no difference between casein and genistein fed mice. In contrast to the HYP prostate, NE carcinoma in this TRAMP model did express neuroendocrine markers, with 80% of sections expressing synaptophysin, and 30% expressing chromogranin. Androgen receptor reactivity diminished from occasional weak positives to uniformly negative. Transgene expression was maintained in NE cells.
[0061] The pattern of estrogen receptor immunoreactivity switched, with nearly complete loss of ERβ expression and gain of ERa expression. The pattern of ERa immunoreactivity was predominantly in clusters of NE cells scattered throughout the tumor mass and not in all NE cells. In data not shown, ERa
expression was also observed in PIN and well-differentiated adenocarcinoma cells in both diet groups. Hence, distinct cancer origins appear to occur in the TRAMP prostate and these are independent of diet.
[0062] In the TRAMP studies described above, PDC appeared to arise predominately in the ventral lobe of the prostate, as also reported by Kaplan-Lefko and Greenberg, 2003. The PDC observed was characterized as being heterogeneous for positive staining with synaptophysin. The PDC likely started as a focus of neuroendocrine cell proliferation, then progressively penetrated the tubules, and proliferated in the stroma, encroaching on adjacent tubules and eventually surrounding the urethra (See progression in FIG. 9A to 9D). FIG. 9A shows basal cells in the prostate ducts are positive for synaptophysin, a marker of neuroendocrine cells. The prostate secretory epithelium is synaptophysin negative. FIG. 9B shows a focus of neuroendocrine cell proliferation, the earliest stage of neuroendocrine-like neoplasia. FIG. 9C shows the neoplastic neuroendocrine cells penetrate through the wall of the prostate tubule and proliferate in the stroma, encroaching adjacent tubules. FIG. 9D shows neoplastic neuroendocrine cells eventually surround the urethra.
[0063] The incidence of PDC has been reported to increase with androgen ablation. In the TRAMP studies, the incidence of well differentiated carcinoma (WDC) was predominantly found in the dorsal lateral prostate and in the ERaKO casein group was significantly (P< 0.00001) higher compared to ERWT casein. On the other hand, the ERaKO casein group has a significantly (p<0.0006) lower frequency of PDC compared to ERWT casein (Table 1 above). However, the incidence of PDC was higher in ERβKO than in ERWT casein (Table 1). One possible explanation is that ERa and ERβ may have opposing roles in the prostate in regard to prostate cancer and that ERa facilitates the development of PDC, while ERβ plays a protective role in prostate cancer. This role is supported in the literature. See e.g., Imamov et al., 2004, and Signoretti et al, 2001. The balance between ERa and ERβ seems to have a significant role in the development of PDC. These data, in conjunction with soy genistein's preferential binding to ERβ, suggest a mechanism by which phytoestrogens may help prevent and/or suppress prostate cancer by binding and regulating ERa, ERβ or both.
[0064] While the foregoing instrumentalities have been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the
art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques and apparatus described above may be used in various combinations. All publications, patents, patent applications, or other documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document were individually indicated to be incorporated by reference for all purposes.
REFERENCES
[0065] Additional information is found in the following publications and references cited within this disclosure, which are hereby incorporated by reference.
Barnes, S., Peterson, G., Grubbs, C, and Setchell, K. D. Potential role of dietary isoflavones in the prevention of cancer. Advances in Experimental Medicine and Biology, 354: 135-147, 1994.
Datta, S. and M.W. Datta, Sonic Hedgehog signaling in advanced prostate cancer. Cell. MoI. Life Sci. 63 (2006) 435-448. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C, and Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res, 57: 3325- 3330, 1997. Goetzl MA, Vanveldhuizen PJ, Thrasher JB., Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis. 2007, Epub ahead of print.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America, 92: 3439-3443, 1995. Guerini, V., Sau, D., Scaccianoce, E., Rusmini, P., Ciana, P., Maggi, A., Martini, P. G., Katzenellenbogen, B. S., Martini, L., Motta, M., and Poletti, A. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res, 65: 5445-5453, 2005. Imamov, O., Morani, A., Shim, G. J., Omoto, Y., Thulin-Andersson, C, Warner, M., and Gustafsson, J. A. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci U S A, 707; 9375-9380, 2004. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007). Cancer Statistics, 2007. CA Cancer J Clin 57(1): 43-66.
Kaplan-Lefko, P. J., Chen, T. M., Ittmann, M. M., Barrios, R. J., Ayala, G. E., Huss, W. J., Maddison, L. A., Foster, B. A., and Greenberg, N. M. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate, 55: 219-237, 2003.
Karhadkar, S. S., Bova, G. S., Abdallah, N., Dhara, S., Gardner, D., Maitra, A.,
Isaacs, J. T., Berman, D. M., and Beachy, P. A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature, 431: 707-712, 2004. Keeler RF. Teratogenic compounds of Veratrum californicum (Durand) X. Cyclopia in rabbits produced by cyclopamine. Teratology 1970;3(2):175-180.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997 138(3):863-70 Meloni AR, Fralish GB, Kelly P, Salahpour A, Chen JK, Wechsler-Reya RJ,
Lefkowitz RJ, Caron MG. Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. MoI Cell Biol 2006;26(20):7550-7560. Mentor-Marcel, R., Lamartiniere, C. A., Eltoum, I. E., Greenberg, N. M., and
Elgavish, A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Research, 61:
6777-6782, 2001.
Prins, G. S., Manner, M., Woodham, C, Chang, W., Kuiper, G., Gustafsson, J. -A., and Birch, L. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology, 139: 874- 883, 1998.
Ruiz i Altaba, A., Sanchez, P., and Dahmane, N. GIi and Hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer, 2: 361-372, 2002. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, Beyna M,
Datta MW, Datta S, Ruiz i Altaba A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci
U S A 2004;101(34):12561-12566. Sanchez, P., Clement, V., and Ruiz i Altaba, A. Therapeutic targeting of the
Hedgehog-GLI pathway in prostate cancer. Cancer Res, 65: 2990-2992, 2005. Shenouda, N., Zhou, C, Browning, J., Ansell, P., Sakla, M., and Lubahn, D. Phytoestrogens in commom herbs regulate prostate cancer cell growth in vitro.
Nutrition and Cancer, 49: 201-209, 2004.
Signoretti, S. and Loda, M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol, 159: 13-16, 2001.
Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(l 1 Pt 1): 1213-21.
Wechter, W. J., Leipold, D. D., Murray, E. D., Quiggle, D., McCracken, J. D., Barrios, R. S., and Greenberg, N. M. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res., 60: 2203- 2208, 2000.
Claims
1. A composition comprising an effective amount of an estrogenic agent, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in a cell.
2. The composition of claim 1, wherein said estrogenic agent comprises a phytoestrogen, or its analog, derivative, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof.
3. The composition of claim 2, wherein the phytoestrogen is at least one member selected from the group consisting of Genistein, Quercetin, Baicalein,
Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
4. The composition of claim 1, wherein said estrogenic agent comprises two or more phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
5. The composition of claim 1, wherein said effective amount is an amount of the estrogenic agent that is effective in reducing the expression of at least one GIi gene by at least 40%.
6. The composition of claim 5, wherein the at least one GIi gene is selected from the group consisting of GIi 1, GH2 and Gli3.
7. The composition of claim 1 wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in a cell by binding to an estrogen receptor in said cell.
8. A method for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual, comprising administering to said individual an effective amount of an estrogenic agent, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in certain cells of said individual.
9. The method of claim 8, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in said individual by binding to an estrogen receptor in said individual.
10. The method of claim 8, wherein said estrogenic agent comprises a phytoestrogen, or its analog, derivative, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof.
11. The method of claim 10, wherein the phytoestrogen is at least one member selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
12. The method of claim 8, wherein said estrogenic agent comprises two or more phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
13. The method of claim 8, wherein said effective amount is an amount of the estrogenic agent that is effective in reducing the expression of at least one GIi gene by at least 40%.
14. The method of claim 13, wherein the at least one GIi gene is selected from the group consisting of GIi 1, GH2 and GH3.
15. A method for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual, comprising administering to said individual an effective amount of an agent, wherein said agent in said effective amount is capable of binding at least one estrogen receptor in the individual, thereby inhibiting the Hedgehog signaling pathway in said individual.
16. The method of claim 15, wherein said agent is an estrogenic agent.
17. A method for inhibiting Hedgehog signaling pathway in an individual with aberrant Hedgehog signaling, comprising: a) determining whether Hedgehog signaling is abnormal in said individual; and b) administering to said individual a Hedgehog signaling inhibiting effective amount of an estrogenic agent.
18. The method of claim 17, wherein said estrogenic agent comprises a phytoestrogen, or its analog, derivative, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof.
19. The method of claim 18, wherein the phytoestrogen is at least one member selected from the group consisting of Genistein, Quercetin, Baicalein,
Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
20. The method of claim 17, wherein said estrogenic agent comprises two or more phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
21. A method for inhibiting Hedgehog signaling pathway in a cell, comprising contacting said cell with an estrogenic agent, said estrogenic agent being present in an amount that is effective in inhibiting expression of at least one GIi gene by at least 40%.
22. The method of claim 21, wherein the GIi gene is selected from the group consisting of GIi 1, Gli2 and Gli3.
23. A method of screening for a potential therapeutic agent for treating or preventing cancer, said method comprising the steps of: (a) contacting a cell with an intact Hedgehog signaling pathway with a candidate molecule;
(b) monitoring changes in the activation of the Hedgehog signaling pathway;
(c) determining whether said molecule is capable of inhibiting the Hedgehog signaling pathway; and (d) identifying said molecule as a potential therapeutic agent if it is determined to be capable of inhibiting the Hedgehog signaling pathway.
24. A molecule identified according to the method of claim 23 to be a potential therapeutic agent.
25. A method for treating cancer, or for preventing the incidence or the recurrence of cancer in an individual, comprising administering to said individual an effective amount of an estrogenic agent, wherein said estrogenic agent in said effective amount is capable of inhibiting the Hedgehog signaling pathway in certain cells of said individual, and said estrogenic agent comprises two or more phytoestrogens selected from the group consisting of Genistein, Quercetin, Baicalein, Apigenin, Daidzein, Neoxanthin, Spinacetin, Patuletin, Luteolin, Curcumin, Resveratrol, EGCG and derivatives thereof.
26. The method of claim 25, wherein said estrogenic agent is a mixture comprising Curcumin, Resveratrol and EGCG.
27. The method of claim 25, wherein said estrogenic agent is a mixture comprising Genistein, Quercetin, Baicalein, and Apigenin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92566107P | 2007-04-20 | 2007-04-20 | |
US60/925,661 | 2007-04-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008131354A2 true WO2008131354A2 (en) | 2008-10-30 |
WO2008131354A3 WO2008131354A3 (en) | 2008-12-31 |
Family
ID=39537552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/061055 WO2008131354A2 (en) | 2007-04-20 | 2008-04-21 | Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment |
Country Status (2)
Country | Link |
---|---|
US (1) | US20090054517A1 (en) |
WO (1) | WO2008131354A2 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2012097000A1 (en) | 2011-01-10 | 2012-07-19 | Pingda Ren | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
WO2013154878A1 (en) | 2012-04-10 | 2013-10-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2014071109A1 (en) | 2012-11-01 | 2014-05-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2014151386A1 (en) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014172456A1 (en) | 2013-04-17 | 2014-10-23 | Hedgepath, Llc | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
WO2014194254A1 (en) | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015143012A1 (en) | 2014-03-19 | 2015-09-24 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
WO2017139497A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9844541B2 (en) | 2012-11-29 | 2017-12-19 | Strasspharma, Llc | Methods of modulating follicle stimulating hormone activity |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9879293B2 (en) | 2009-08-05 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
EP3303289A4 (en) * | 2015-06-05 | 2018-11-14 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
US10369147B2 (en) | 2015-06-04 | 2019-08-06 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20130366A1 (en) * | 2013-06-25 | 2014-12-26 | Univ Roma La Sapienza | MULTITARGET HEDGEHOG PATHWAY INHIBITORS AND USES THEREOF |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002056823A2 (en) * | 2001-01-18 | 2002-07-25 | Arnold Hoffman | Redox therapy for tumors |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US20040063648A1 (en) * | 2002-10-01 | 2004-04-01 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
WO2005092121A2 (en) * | 2004-03-19 | 2005-10-06 | Nestec S.A. | Delivery of functional ingredients |
WO2005094864A2 (en) * | 2004-03-30 | 2005-10-13 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis |
WO2005107370A2 (en) * | 2004-05-10 | 2005-11-17 | Redoxia Israel Ltd | Kit for treatment of cancer |
US20060172012A1 (en) * | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
WO2007062415A1 (en) * | 2005-11-26 | 2007-05-31 | Grinrx | Corporeal delivery of carotenoids |
WO2007131767A2 (en) * | 2006-05-15 | 2007-11-22 | Dsm Ip Assets B.V. | Novel actives against prostate carcinoma |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69333624T2 (en) * | 1992-05-19 | 2005-09-15 | Novogen Research Pty. Ltd., North Ryde | USE OF ISOFLAVON PHYTO-ESTROGEN EXTRACTS OF SOY OR CLOVER |
US6300367B1 (en) * | 1999-04-20 | 2001-10-09 | Protein Technologies International, Inc. | Composition for and method of preventing or treating breast cancer |
-
2008
- 2008-04-21 WO PCT/US2008/061055 patent/WO2008131354A2/en active Application Filing
- 2008-04-21 US US12/106,993 patent/US20090054517A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002056823A2 (en) * | 2001-01-18 | 2002-07-25 | Arnold Hoffman | Redox therapy for tumors |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US20040063648A1 (en) * | 2002-10-01 | 2004-04-01 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
WO2005092121A2 (en) * | 2004-03-19 | 2005-10-06 | Nestec S.A. | Delivery of functional ingredients |
WO2005094864A2 (en) * | 2004-03-30 | 2005-10-13 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis |
WO2005107370A2 (en) * | 2004-05-10 | 2005-11-17 | Redoxia Israel Ltd | Kit for treatment of cancer |
US20060172012A1 (en) * | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
WO2007062415A1 (en) * | 2005-11-26 | 2007-05-31 | Grinrx | Corporeal delivery of carotenoids |
WO2007131767A2 (en) * | 2006-05-15 | 2007-11-22 | Dsm Ip Assets B.V. | Novel actives against prostate carcinoma |
Non-Patent Citations (2)
Title |
---|
BARNES S ET AL: "POTENTIAL ROLE OF DIETARY ISOFLAVONES IN THE PREVENTION OF CANCER" 1 January 1994 (1994-01-01), ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, PAGE(S) 135 - 147 , XP002077082 ISSN: 0065-2598 cited in the application the whole document page 136, paragraphs 2,3 page 139, last paragraph - page 142, paragraph 1 page 144, paragraph 3 * |
ROYCELYNN MENTOR-MARCEL ET AL.: "Genistein in the Diet Reduces the Incidence of Poorly Differentiated Prostatic Adenocarcinoma in Transgenic Mice (TRAMP)" CANCER RESEARCH, vol. 61, 15 September 2001 (2001-09-15), pages 6777-6782, XP002486385 cited in the application * |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406139B2 (en) | 2006-12-28 | 2019-09-10 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US9492435B2 (en) | 2006-12-28 | 2016-11-15 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US11007181B2 (en) | 2006-12-28 | 2021-05-18 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US9951083B2 (en) | 2006-12-28 | 2018-04-24 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogs |
US11602527B2 (en) | 2006-12-28 | 2023-03-14 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9669011B2 (en) | 2006-12-28 | 2017-06-06 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US10821102B2 (en) | 2006-12-28 | 2020-11-03 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US10314827B2 (en) | 2006-12-28 | 2019-06-11 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US10045970B2 (en) | 2006-12-28 | 2018-08-14 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9145422B2 (en) | 2006-12-28 | 2015-09-29 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US8895576B2 (en) | 2006-12-28 | 2014-11-25 | Infinity Pharmaceuticals, Inc. | Methods of use of cyclopamine analogs |
US9238672B2 (en) | 2007-12-27 | 2016-01-19 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9879293B2 (en) | 2009-08-05 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9879025B2 (en) | 2010-09-14 | 2018-01-30 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2012097000A1 (en) | 2011-01-10 | 2012-07-19 | Pingda Ren | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
EP3581574A1 (en) | 2011-01-10 | 2019-12-18 | Infinity Pharmaceuticals, Inc. | A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
EP3238722A1 (en) | 2011-01-10 | 2017-11-01 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
WO2013154878A1 (en) | 2012-04-10 | 2013-10-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2014071109A1 (en) | 2012-11-01 | 2014-05-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
US9844541B2 (en) | 2012-11-29 | 2017-12-19 | Strasspharma, Llc | Methods of modulating follicle stimulating hormone activity |
WO2014151386A1 (en) | 2013-03-15 | 2014-09-25 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2014172456A1 (en) | 2013-04-17 | 2014-10-23 | Hedgepath, Llc | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
US10363252B2 (en) | 2013-04-17 | 2019-07-30 | Hedgepath Pharmaceuticals, Inc. | Treatment of prostate cancer using hedgehog pathway inhibitors |
US10328072B2 (en) | 2013-04-17 | 2019-06-25 | Hedgepath Pharmaceuticals, Inc. | Treatment of lung cancer using hedgehog pathway inhibitors |
US9962381B2 (en) | 2013-04-17 | 2018-05-08 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors |
US9968600B2 (en) | 2013-04-17 | 2018-05-15 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
WO2014194254A1 (en) | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
EP3811974A1 (en) | 2013-05-30 | 2021-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015143012A1 (en) | 2014-03-19 | 2015-09-24 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10695344B2 (en) | 2015-06-04 | 2020-06-30 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US11413283B2 (en) | 2015-06-04 | 2022-08-16 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US10369147B2 (en) | 2015-06-04 | 2019-08-06 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US10934256B2 (en) | 2015-06-05 | 2021-03-02 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
US10464897B2 (en) | 2015-06-05 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
EP3303289A4 (en) * | 2015-06-05 | 2018-11-14 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
US11845728B2 (en) | 2015-06-05 | 2023-12-19 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
WO2017139497A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Also Published As
Publication number | Publication date |
---|---|
WO2008131354A3 (en) | 2008-12-31 |
US20090054517A1 (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090054517A1 (en) | Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment | |
Aiyer et al. | Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention | |
Moutsatsou | The spectrum of phytoestrogens in nature: our knowledge is expanding | |
Stabile et al. | Estrogen receptor pathways in lung cancer | |
Bulzomi et al. | The pro‐apoptotic effect of quercetin in cancer cell lines requires ERβ‐dependent signals | |
Chiang et al. | Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation | |
Le Naour et al. | EO771, the first luminal B mammary cancer cell line from C57BL/6 mice | |
Brown et al. | Genistein modulates neuroblastoma cell proliferation and differentiation through induction of apoptosis and regulation of tyrosine kinase activity and N-myc expression. | |
Morrissey et al. | Phytoestrogens and prostate cancer | |
Zimmermann et al. | Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy | |
Benmansour et al. | Effects of long-term treatment with estradiol and estrogen receptor subtype agonists on serotonergic function in ovariectomized rats | |
Malafa et al. | Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis | |
Oudard et al. | Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts | |
Kumar et al. | Activating stress-activated protein kinase–mediated cell death and inhibiting epidermal growth factor receptor signaling: A promising therapeutic strategy for prostate cancer | |
Chen et al. | Dietary tocopherols inhibit PhIP-induced prostate carcinogenesis in CYP1A-humanized mice | |
Chen et al. | Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells | |
Xu et al. | Biological effects of xenoestrogens and the functional mechanisms via genomic and nongenomic pathways | |
Pineiro et al. | GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism | |
Cui et al. | Dihydroartemisinin sensitizes esophageal squamous cell carcinoma to cisplatin by inhibiting sonic hedgehog signaling | |
US9782393B2 (en) | Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening | |
A Nguewa et al. | Use of transgenic mice as models for prostate cancer chemoprevention | |
Zhang et al. | Anesthetic propofol inhibits ferroptosis and aggravates distant cancer metastasis via Nrf2 upregulation | |
Bolli et al. | Current and future development of estrogen receptor ligands: applications in estrogen-related cancers | |
Jahanafrooz et al. | Influence of silibinin and β-β-dimethylacrylshikonin on chordoma cells | |
Kinjo et al. | Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08746465 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08746465 Country of ref document: EP Kind code of ref document: A2 |